Miriam Schulz is an impact-driven translational scientist specializing in T cell immunology, with expertise in preclinical and clinical research, medical affairs, and project management. They served as a Teaching Assistant at Harvard T.H. Chan School of Public Health in 2022 and completed research training in basic biomedical cancer research at Cardiff University School of Medicine in 2016. Currently working as a PhD candidate at Klinikum rechts der Isar, TUM, they focus on the pathogenesis of T cell lymphoma and related therapies. Miriam has also held positions at AstraZeneca and Pfizer, contributing to medical affairs in hematology and drug surveillance. They are pursuing a PhD in Experimental Medicine at Technische Universität München.
This person is not in the org chart
This person is not in any teams
This person is not in any offices